As a result of these false statements and/or omissions, the price of Celgene stock was artificially inflated during the Class Period to over $145 per share. On October 19, 2017, the Company revealed that it would be abandoning GED-0301, …
Celgene could be a bargain buy if it can overcome some challenges. Celgene could be a bargain buy if it can overcome some challenges. Home Mail Search News Finance Sport Lifestyle Celebrity Movies Weather Flickr More Yahoo …
The Klein Law Firm announces the commencement of an investigation of Celgene Corporation (NASDAQGS:CELG) …
Let’s just say, the last few quarters have not been biotech superstar Celgene’s (NASDAQ:CELG) best couple of months. The biotech stock has been hit by wave after wave of bad news, stumbles and declines. So much so, that investors …
But should investors stay clear of Celgene stock after the big blunder, or is now a great time to buy? Celgene stated that "the FDA determined that the nonclinical and clinical pharmacology sections in the NDA were insufficient to permit a …
When stocks hit multiyear lows, there's usually an earnings contraction to point a finger at. That's not the case at Celgene Corporation (NASDAQ: CELG). Profits in 2018 are expected to be around three times higher than they were in 2014, …